Paget’s disease of bone: an osteoimmunological disorder?

References

• TavianMPeaultBEmbryonic development of the human hematopoietic systemInt J Dev Biol2005492–324325015906238
   PubMed Web of Science ®Google Scholar
• Regenerative MedicineIn Stem Cell Information [World Wide Web Site] Chapter 5Bethesda, MDNational Institutes of Health, U.S. Department of Health and Human Services2011 [cited Monday, May 18, 2015]. Available from: http://stemcells.nih.gov/info/scireport/Pages/2006report.aspxAccessed February 11, 2015
   Google Scholar
• JonesDLWagersAJNo place like home: anatomy and function of the stem cell nicheNat Rev Mol Cell Biol200891112118097443
   PubMed Web of Science ®Google Scholar
• OrkinSHDevelopment of the hematopoietic systemCurr Opin Genet Dev1996655976028939717
   PubMed Web of Science ®Google Scholar
• OrkinSHZonLIHematopoiesis and stem cells: plasticity versus developmental heterogeneityNat Immunol20023432332811919568
   PubMed Web of Science ®Google Scholar
• JonesDHKongYYPenningerJMRole of RANKL and RANK in bone loss and arthritisAnn Rheum Dis200261suppl 2ii32ii3912379618
   PubMedGoogle Scholar
• ZhaoBIvashkivLBNegative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressorsArthritis Res Ther201113423421861861
   PubMed Web of Science ®Google Scholar
• YinTLiLThe stem cell niches in boneJ Clin Invest200611651195120116670760
   PubMed Web of Science ®Google Scholar
• ImaiYYounMYInoueKTakadaIKouzmenkoAKatoSNuclear receptors in bone physiology and diseasesPhysiol Rev201393248152323589826
   PubMed Web of Science ®Google Scholar
• HadjidakisDJAndroulakisIIBone remodelingAnn N Y Acad Sci2006109238539617308163
   PubMed Web of Science ®Google Scholar
• LorenzoJChoiYOsteoimmunologyImmunol Rev20052085616313336
   PubMed Web of Science ®Google Scholar
• Bar-ShavitZThe osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cellJ Cell Biochem200710251130113917955494
   PubMed Web of Science ®Google Scholar
• WongBRRhoJArronJTRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cellsJ Biol Chem19972724025190251949312132
   PubMed Web of Science ®Google Scholar
• WuytsWVan WesenbeeckLMorales-PigaAEvaluation of the role of RANK and OPG genes in Paget’s disease of boneBone200128110410711165949
   PubMed Web of Science ®Google Scholar
• RoodmanGDGalsonDLThe Origins of Bone Cells: Osteoclasts Chapter 2, OsteoimmunologyVol Osteoimmunology1st ed2011
   Google Scholar
• LorenzoJHorowitzMChoiYSchettGTakayanagiHOsteoimmunology: Interactions of the Immune and Skeletal Systems Chapter 2Academic Press ElsevierLondon2010
   Google Scholar
• RichesPLMcRorieEFraserWDDetermannCvan’t HofRRalstonSHOsteoporosis associated with neutralizing autoantibodies against osteoprotegerinN Engl J Med2009361151459146519812402
   PubMed Web of Science ®Google Scholar
• AndersonDMMaraskovskyEBillingsleyWLA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature199739066561751799367155
   PubMed Web of Science ®Google Scholar
• JungSMKimKWYangCWParkSHJuJHCytokine-mediated bone destruction in rheumatoid arthritisJ Immunol Res2014201426362525295284
   PubMed Web of Science ®Google Scholar
• SchettGGravalleseEBone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatmentNat Rev Rheumatol201281165666423007741
   PubMed Web of Science ®Google Scholar
• DanksLTakayanagiHImmunology and boneJ Biochem20131541293923750028
   PubMed Web of Science ®Google Scholar
• KongYYFeigeUSarosiIActivated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature1999402675930430910580503
   PubMed Web of Science ®Google Scholar
• MahoneyDJMikeczKAliTTSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activationJ Biol Chem200828338259522596218586671
   PubMed Web of Science ®Google Scholar
• ZawawiMSDharmapatniAACantleyMDMcHughKPHaynesDRCrottiTNRegulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiationBiochem Biophys Res Commun2012427240440923000414
   PubMed Web of Science ®Google Scholar
• HumphreyMBLanierLLNakamuraMCRole of ITAM-containing adapter proteins and their receptors in the immune system and boneImmunol Rev2005208506516313340
   PubMed Web of Science ®Google Scholar
• NumanMSBrownJPMichouLImpact of air pollutants on oxidative stress in common autophagy-mediated aging diseasesInt J Environ Res Public Health20151222289230525690002
   PubMed Web of Science ®Google Scholar
• MichouLColletCLaplancheJLOrcelPCornelisFGenetics of Paget’s disease of boneJoint Bone Spine200673324324816574459
   PubMed Web of Science ®Google Scholar
• AlbaghaOMWaniSEViscontiMRGenetic Determinants of Paget’s Disease (GDPD) ConsortiumGenome-wide association identifies three new susceptibility loci for Paget’s disease of boneNat Genet201143768568921623375
   PubMed Web of Science ®Google Scholar
• ReaSLWalshJPLayfieldRRatajczakTXuJNew insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget’s disease of boneEndocr Rev201334450152423612225
   PubMed Web of Science ®Google Scholar
• LayfieldRCianiBRalstonSHStructural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget’s disease of boneBiochem Soc Trans200432pt 572873015493999
   PubMedGoogle Scholar
• GoodeALayfieldRRecent advances in understanding the molecular basis of Paget disease of boneJ Clin Pathol201063319920319858527
   PubMed Web of Science ®Google Scholar
• CoppleIMListerAObengADPhysical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathwayJ Biol Chem201028522167821678820378532
   PubMed Web of Science ®Google Scholar
• MathewRKarpCMBeaudoinBAutophagy suppresses tumorigenesis through elimination of p62Cell200913761062107519524509
   PubMed Web of Science ®Google Scholar
• NealeSDSchulzeESmithRAthanasouNAThe influence of serum cytokines and growth factors on osteoclast formation in Paget’s diseaseQJM200295423324011937650
   PubMed Web of Science ®Google Scholar
• KudoOSabokbarAPocockAItonagaIFujikawaYAthanasouNAInterleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanismBone20033211712584029
   PubMed Web of Science ®Google Scholar
• HirayamaTSabokbarAAthanasouNAEffect of corticosteroids on human osteoclast formation and activityJ Endocrinol2002175115516312379499
   PubMed Web of Science ®Google Scholar
• AlbaghaOMViscontiMRAlonsoNGenome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of boneNat Genet201042652052420436471
   PubMed Web of Science ®Google Scholar
• RezaieTChildAHitchingsRAdult-onset primary open-angle glaucoma caused by mutations in optineurinScience200229555571077107911834836
   PubMed Web of Science ®Google Scholar
• YingHYueBYCellular and molecular biology of optineurinInt Rev Cell Mol Biol201229422322364875
   PubMed Web of Science ®Google Scholar
• MankouriJFragkoudisRRichardsKHOptineurin negatively regulates the induction of IFNβ in response to RNA virus infectionPLoS Pathog201062e100077820174559
   PubMed Web of Science ®Google Scholar
• MortonSHessonLPeggieMCohenPEnhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucomaFEBS Lett20085826997100218307994
   PubMed Web of Science ®Google Scholar
• SingerFRThe etiology of Paget’s disease of bone: viral and genetic interactionsCell Metab20111315621195342
   PubMed Web of Science ®Google Scholar
• RalstonSHLayfieldRPathogenesis of Paget disease of boneCalcif Tissue Int20129129711322543925
   PubMed Web of Science ®Google Scholar
• EhrlichLARoodmanGDThe role of immune cells and inflammatory cytokines in Paget’s disease and multiple myelomaImmunol Rev200520825226616313353
   PubMed Web of Science ®Google Scholar
• TakayanagiHOsteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNat Rev Immunol20077429230417380158
   PubMed Web of Science ®Google Scholar
• MurabayashiNKurita-TaniguchiMAyataMMatsumotoMOguraHSeyaTSusceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of toll stimulators in DC maturation and MV amplificationMicrobes Infect20024878579412270725
   PubMed Web of Science ®Google Scholar
• NagyZBGergelyPDonathJBorgulyaGCsanadMPoorGGene expression profiling in Paget’s disease of bone: upregulation of interferon signaling pathways in pagetic monocytes and lymphocytesJ Bone Miner Res200823225325918197754
   PubMed Web of Science ®Google Scholar
• SchwarzPRasmussenAQKvistTMAndersenUBJorgensenNRPaget’s disease of the bone after treatment with Denosumab: a case reportBone20125051023102522586699
   PubMed Web of Science ®Google Scholar
• GalsonDLRoodmanGDPathobiology of Paget’s disease of boneJ Bone Metab2014212859825025000
   PubMedGoogle Scholar
• MichouLBrownJPEmerging strategies and therapies for treatment of Paget’s disease of boneDrug Des Devel Ther20115225239
   Web of Science ®Google Scholar
• MillsBGFraustoACytokines expressed in multinucleated cells: Paget’s disease and giant cell tumors versus normal boneCalcif Tissue Int199761116219192505
   PubMed Web of Science ®Google Scholar
• Francisco-CruzAAguilar-SantelisesMRamos-EspinosaOGranulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factorMed Oncol201431177424264600
   PubMed Web of Science ®Google Scholar
• WangYNishidaSElaliehHZLongRKHalloranBPBikleDDRole of IGF-I signaling in regulating osteoclastogenesisJ Bone Miner Res20062191350135816939393
   PubMed Web of Science ®Google Scholar
• SchoenbornJRWilsonCBRegulation of interferon-gamma during innate and adaptive immune responsesAdv Immunol2007964110117981204
   PubMed Web of Science ®Google Scholar
• SokolCLBartonGMFarrAGMedzhitovRA mechanism for the initiation of allergen-induced T helper type 2 responsesNat Immunol20089331031818300366
   PubMed Web of Science ®Google Scholar
• GarlisiCGFalconeABillahMMEganRWUmlandSPT cells are the predominant source of interleukin-5 but not interleukin-4 mRNA expression in the lungs of antigen-challenged allergic miceAm J Respir Cell Mol Biol19961534204288810648
   PubMed Web of Science ®Google Scholar
• GarciaGTailleCLavenezianaPBourdinAChanezPHumbertMAnti-interleukin-5 therapy in severe asthmaEur Respir Rev20132212925125723997052
   PubMedGoogle Scholar
• ZhangQChenBYanFInterleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseasesBiomed Res Int2014201428483624696846
   PubMed Web of Science ®Google Scholar
• HymowitzSGFilvaroffEHYinJPIL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor bindingEMBO J200120195332534111574464
   PubMed Web of Science ®Google Scholar
• StanleyERBergKLEinsteinDBBiology and action of colony – stimulating factor-1Mol Reprod Dev19974614108981357
   PubMed Web of Science ®Google Scholar
• UdagawaNTakahashiNJimiEOsteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligandBone199925551752310574571
   PubMed Web of Science ®Google Scholar
• ChamouxEHoudeNL’ErigerKRouxSOsteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathwayJ Cell Physiol2008216253654218338379
   PubMed Web of Science ®Google Scholar
• ItonagaISabokbarASunSGTransforming growth factor-beta induces osteoclast formation in the absence of RANKLBone2004341576414751563
   PubMed Web of Science ®Google Scholar
• Online Mendelian Inheritance in Man® (OMIM®)Tumor Necrosis Factor (TNF), OMIM 1911602015 Available from: http://www.omim.org/entry/191160Accessed March 3, 2015
   Google Scholar
• ZhangJFuQRenZChanges of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosisGynecol Endocrinol201531318390 Epub 2014 Nov 1125384921
   PubMed Web of Science ®Google Scholar
• Al-ZahraniMKElnasiehAMAleneziFMA 3-month oral vitamin D supplementation marginally improves diastolic blood pressure in Saudi patients with type 2 diabetes mellitusInt J Clin Exp Med20147125421542825664051
   PubMed Web of Science ®Google Scholar
• AlvarezLPerisPGuañabensNLong-term biochemical response after bisphosphonate therapy in Paget’s disease of bone. Proposed intervals for monitoring treatmentRheumatology200443786987415054158
   PubMed Web of Science ®Google Scholar
• MarshallMJEvansSFSharpCAPowellDEMcCarthyHSDavieMWIncreased circulating dickkopf-1 in Paget’s disease of boneClin Biochem20094210–1196596919389391
   PubMed Web of Science ®Google Scholar
• PolyzosSAAnastasilakisADEfstathiadouZThe effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget’s disease of boneHorm Metab Res2009411184685019670154
   PubMed Web of Science ®Google Scholar
• Werner de CastroGRBussZDa RosaJSFrodeTSInflammatory cytokines in Paget’s disease of boneInt Immunopharmacol201418227728124355795
   PubMed Web of Science ®Google Scholar
• YavropoulouMPvan LieropAHHamdyNARizzoliRPapapoulosSESerum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnoverBone201251115315722579776
   PubMed Web of Science ®Google Scholar
• RossiniMViapianaOAdamiSIn patients with rheumatoid arthritis, dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral densityClin Exp Rheumatol2015331778325438096
   PubMed Web of Science ®Google Scholar
• HongQXuJXuSLianLZhangMDingCAssociations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritisRheumatology201453111994200124907153
   PubMed Web of Science ®Google Scholar
• CortetBCottenABoutryNPercutaneous vertebroplasty in patients with osteolytic metastases or multiple myelomaRev Rhum1997643177183
   Google Scholar
• Al-AwadhiAOlusiSAl-ZaidNPrabhaKSerum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritisJ Rheumatol19992661250125610381038
   PubMed Web of Science ®Google Scholar
• SerioloBFerrettiVSulliACarattoEFascioloDCutoloMSerum osteocalcin levels in premenopausal rheumatoid arthritis patientsAnn N Y Acad Sci200296650250712114311
   PubMed Web of Science ®Google Scholar
• WongPKYoungLVaileJHTelopeptides as markers of bone turnover in rheumatoid arthritis and osteoarthritisIntern Med J2004349–1053954415482266
   PubMed Web of Science ®Google Scholar
• LongLLiuYWangSDickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosusJ Clin Immunol201030566967520589421
   PubMed Web of Science ®Google Scholar
• HeardBJRosvoldJMFritzlerMJEl-GabalawyHWileyJPKrawetzRJA computational method to differentiate normal individuals, osteoarthritis and rheumatoid arthritis patients using serum biomarkersJ R Soc Interface201411972014042824920114
   PubMed Web of Science ®Google Scholar
• JiHILeeSHSongRSerum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritisClin Rheumatol201433339740223995733
   PubMed Web of Science ®Google Scholar
• KorczowskaIOlewicz-GawlikAHrycajPLackiJThe effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorptionYale J Biol Med2003762455415369631
   PubMedGoogle Scholar
• RulloOJWooJMParsaMFPlasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosusArthritis Res Ther2013151R1823343383
   PubMed Web of Science ®Google Scholar
• Lyn-CookBDXieCOatesJIncreased expression of toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugsMol Immunol2014611384324865418
   PubMed Web of Science ®Google Scholar
• VincentFBNorthcottMHoiAMackayFMorandEFClinical associations of serum interleukin-17 in systemic lupus erythematosusArthritis Res Ther201315R9723968496
   PubMed Web of Science ®Google Scholar
• La MontagnaGBaruffoAAbbadessaSMajaLTirriREvidence for bone resorption in systemic sclerosisJ Rheumatol19952247977997791196
   PubMed Web of Science ®Google Scholar
• IštokRCzirjákLLukáčJStančíkováMRovenskýJIncreased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud’s phenomenonRheumatology200140214014611257149
   PubMed Web of Science ®Google Scholar
• AtteritanoMSorbaraSBagnatoGBone mineral density, bone turnover markers and fractures in patients with systemic sclerosis: a case control studyPLoS One201386e6699123818972
   PubMed Web of Science ®Google Scholar
• AllanoreYBorderieDLemaréchalHCherruauBEkindjianOGKahanACorrelation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosisJ Rheumatol2003301687312508392
   PubMed Web of Science ®Google Scholar
• MackoRFGelberACYoungBAIncreased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activationJ Rheumatol200229122565257012465153
   PubMed Web of Science ®Google Scholar
• CastellinoGCoralliniFBortoluzziAThe tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?Rheumatology20104961173117620299382
   PubMed Web of Science ®Google Scholar
• DovioADataVCarignolaRCirculating osteoprotegerin and soluble RANK ligand in systemic sclerosisJ Rheumatol200835112206221318843778
   PubMed Web of Science ®Google Scholar
• MaekawaTKomineMMurataSOhtsukiMPeritoneal loose body: a case report and comparison with encapsulated fat necrosisJ Dermatol201340121058105924330174
   PubMed Web of Science ®Google Scholar
• AndersenGNNilssonKNagaevaORantapaa-DahlqvistSSandstromTMincheva-NilssonLCytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 responseScand J Immunol201174327228121535076
   PubMed Web of Science ®Google Scholar
• WuMSchneiderDJMayesMDOsteopontin in systemic sclerosis and its role in dermal fibrosisJ Invest Dermatol201213261605161422402440
   PubMed Web of Science ®Google Scholar
• Olewicz-GawlikADanczak-PazdrowskaAKuznar-KaminskaBInterleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosisInt J Rheum Dis201417666467024467649
   PubMed Web of Science ®Google Scholar
• PehlivanYOnatAMCeylanNSerum leptin, resistin and TNF-alpha levels in patients with systemic sclerosis: the role of adipokines in sclerodermaInt J Rheum Dis201215437437922898217
   PubMed Web of Science ®Google Scholar
• HasegawaMSatoSFujimotoMIhnHKikuchiKTakeharaKSerum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosisJ Rheumatol19982523083139489824
   PubMed Web of Science ®Google Scholar
• KimWUMinSYChoMLElevated matrix metalloproteinase-9 in patients with systemic sclerosisArthritis Res Ther200571R71R7915642145
   PubMed Web of Science ®Google Scholar
• PantsulaiaIKalichmanLKobylianskyEAssociation between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markersOsteoarthr Cartil201018111448145320633673
   PubMed Web of Science ®Google Scholar
• KummJTammALintropMDiagnostic and prognostic value of bone biomarkers in progressive knee osteoarthritis: a 6-year follow-up study in middle-aged subjectsOsteoarthr Cartil201321681582223523608
   PubMed Web of Science ®Google Scholar
• DalbethNPoolBSmithTCirculating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosionArthritis Res Ther2010124R16420796300
   PubMed Web of Science ®Google Scholar
• GrisarJBerneckerPMAringerMAnkylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formationJ Rheumatol20022971430143612136902
   PubMed Web of Science ®Google Scholar
• AmitalHBarakVWinklerRERubinowAImpact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritisAnn N Y Acad Sci20071110164966017911480
   PubMedGoogle Scholar
• TaylanASariIAkinciBBiomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitisBMC Musculoskelet Disord20121319123025387
   PubMed Web of Science ®Google Scholar
• MarhofferWStrackeHMasoudIEvidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitisAnn Rheum Dis19955475565597668898
   PubMed Web of Science ®Google Scholar
• ToussirotERicard-BlumSDumoulinGCedozJWendlingDRelationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitisRheumatology1999381212710334678
   PubMed Web of Science ®Google Scholar
• MitraDElvinsDCollinsABiochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fracturesJ Rheumatol199926102201220410529140
   PubMed Web of Science ®Google Scholar
• YilmazNOzaslanJBiochemical bone turnover markers in patients with ankylosing spondylitisClin Rheumatol2000192929810791618
   PubMed Web of Science ®Google Scholar
• ParkMCChungSJParkYBLeeSKBone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitisYonsei Med J200849228829418452267
   PubMed Web of Science ®Google Scholar
• VosseDLandeweRGarneroPvan der HeijdeDvan der LindenSGeusensPAssociation of markers of bone-and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitisRheumatology20084781219122218539620
   PubMed Web of Science ®Google Scholar
• MeiYPanFGaoJIncreased serum IL-17 and IL-23 in the patient with ankylosing spondylitisClin Rheumatol201130226927321161669
   PubMed Web of Science ®Google Scholar
• BalAUnluEBaharGAydogEEksiogluEYorganciogluRComparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitisClin Rheumatol200726221121516583185
   PubMed Web of Science ®Google Scholar
• FranckHMeurerTHofbauerLCEvaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitisJ Rheumatol200431112236224115517638
   PubMed Web of Science ®Google Scholar
• HouLTLiuCMLiuBYLinSJLiaoCSRossomandoEFInterleukin-1beta, clinical parameters and matched cellular-histopathologic changes of biopsied gingival tissue from periodontitis patientsJ Periodontal Res200338324725412753361
   PubMed Web of Science ®Google Scholar
• TakeichiOHaberJKawaiTSmithDJMoroITaubmanMACytokine profiles of T-lymphocytes from gingival tissues with pathological pocketingJ Dent Res20007981548155511023273
   PubMed Web of Science ®Google Scholar
• KawaiTMatsuyamaTHosokawaYB and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal diseaseAm J Pathol2006169398799816936272
   PubMed Web of Science ®Google Scholar
• OhyamaHKato-KogoeNKuharaAThe involvement of IL-23 and the Th17 pathway in periodontitisJ Dent Res200988763363819605880
   PubMed Web of Science ®Google Scholar
• MalhotraRGroverVKapoorAKapurRAlkaline phosphatase as a periodontal disease markerIndian J Dent Res201021453121187620
   PubMedGoogle Scholar
• MarcacciniAMNovaesABJrMeschiariCACirculating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapyClin Chim Acta20094091–211712219751716
   PubMed Web of Science ®Google Scholar
• NakajimaTHondaTDomonHPeriodontitis-associated upregulation of systemic inflammatory mediator level may increase the risk of coronary heart diseaseJ Periodontal Res201045111612219602107
   PubMed Web of Science ®Google Scholar
• DuartePMda RochaMSampaioESerum levels of cytokines in subjects with generalized chronic and aggressive periodontitis before and after non-surgical periodontal therapy: a pilot studyJ Periodontol20108171056106320192617
   PubMed Web of Science ®Google Scholar
• LiuKMengHTangXElevated plasma calcifediol is associated with aggressive periodontitisJ Periodontol20098071114112019563291
   PubMed Web of Science ®Google Scholar
• ZhangXMengHSunXElevation of vitamin D-binding protein levels in the plasma of patients with generalized aggressive periodontitisJ Periodontal Res2013481747922803589
   PubMed Web of Science ®Google Scholar
• MiricescuDTotanACalenicBSalivary biomarkers: relationship between oxidative stress and alveolar bone loss in chronic periodontitisActa Odontol Scand2014721424723869629
   PubMed Web of Science ®Google Scholar
• OzcakaONalbantsoyABicakciNKoseTBuduneliNPlasma levels of C-telopeptide pyridinoline cross-links of type I collagen and osteocalcin in chronic periodontitisInflammation201134320320820577791
   PubMed Web of Science ®Google Scholar
• GursoyUKKönönenEPradhan-PalikhePSalivary MMP-8, TIMP-1, and ICTP as markers of advanced periodontitisJ Clin Periodontol201037648749320507371
   PubMed Web of Science ®Google Scholar
• HansSMaliAMEstimation and comparison of osteopontin levels in plasma in subjects with healthy periodontium and generalized chronic periodontitis and its assessment after scaling and root planingJ Indian Soc Periodontol201216335435723162328
   PubMedGoogle Scholar
• Kone-PautIGaleottiCAnakinra for cryopyrin-associated periodic syndromeExpert Rev Clin Immunol201410171824308832
   PubMed Web of Science ®Google Scholar
• CavalliGFranchiniSAielloPEfficacy and safety of biological agents in adult-onset Still’s diseaseScand J Rheumatol201516
   Web of Science ®Google Scholar
• SayginCUzunaslanDHatemiGCurrently used biologic agents in the management of Behcet’s syndromeCurr Med Chem201522161976198525666786
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information, Arcalyst [rilonacept]Regeneron Pharmaceuticals, Inc Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdfAccessed October 20, 2014
   Google Scholar
• European Medicines Agency Docs2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdfAccessed February 28, 2015
   Google Scholar
• CantariniLLopalcoGCasoFEffectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet’s diseaseAutoimmun Rev20151411925151975
   PubMed Web of Science ®Google Scholar
• PRODUCT MONOGRAPH, ACTEMRA® [tocilizumab]2015 Available from: http://www.rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/ConsumerInformation/Monographsand-PublicAdvisories/Actemra/Actemra_PM_E.pdfAccessed February 28, 2015
   Google Scholar
• MPRIxekizumab vs Etanercept for Plaque Psoriasis: Phase 3 Results Announced2015 Available from: http://www.empr.com/ixekizumab-vs-etanercept-for-plaque-psoriasis-phase-3-results-announced/article/367354/Accessed February 28, 2015
   Google Scholar
• Novartis Pharmaceuticals Canada IncSecukinumab [AIN457]2015 Available from: http://www.novartis.ca/cs/www.novartis.ca-v2/downloads/en/News/Novartis_PR_Nov172014_EN.pdfAccessed February 28, 2015
   Google Scholar
• MPRBrodalumab Demonstrates Efficacy in Plaque Psoriasis Study2015 Available from: http://www.empr.com/ixekizumab-vs-etanercept-for-plaque-psoriasis-phase-3-results-announced/article/367354/Accessed February 28, 2015
   Google Scholar
• JANSSEN, STELARA®2015 Available from: http://www.janssen.ca/product/190Accessed February 28, 2015
   Google Scholar
• CundyTDavidsonJRutlandMDStewartCDePaoliAMRecombinant osteoprotegerin for juvenile Paget’s diseaseN Engl J Med2005353991892316135836
   PubMed Web of Science ®Google Scholar
• PRODUCT MONOGRAPH PROLIA [denosumab]2015 Available from: https://www.amgen.ca/Prolia_PM.pdfAccessed February 28, 2015
   Google Scholar
• PRODUCT MONOGRAPH XGEVA [denosumab]2015 Available from: https://www.amgen.ca/Xgeva_PM.pdfAccessed February 28, 2015
   Google Scholar
• GrasemannCSchündelnMMHövelMEffects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s diseaseJ Clin Endocrinol Metab20139883121312623788687
   PubMed Web of Science ®Google Scholar
• PolyzosSASinghellakisPNNaotDDenosumab treatment for juvenile Paget’s disease: results from two adult patients with osteoprotegerin deficiency (“Balkan” mutation in the TNFRSF11B gene)J Clin Endocrinol Metab201499370370724433001
   PubMed Web of Science ®Google Scholar
• PRODUCT MONOGRAPH ENBREL [etanercept]2015 Available from: https://www.amgen.ca/Enbrel_PM.pdfAccessed February 28, 2015
   Google Scholar
• PRODUCT MONOGRAPH REMICADE [infliximab]2015 Available from: http://www.mun.ca/pharmacy/aboutpharmacy/REMICADEPME.pdfAccessed February 28, 2015
   Google Scholar
• PRODUCT MONOGRAPH, HUMIRA® [adalimumab]2015 Available from: http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HUMIRA_PM_EN.pdfAccessed February 28, 2015
   Google Scholar
• PRODUCT MONOGRAPH SIMPONI [golimumab]2015 Available from: http://www.mun.ca/pharmacy/aboutpharmacy/SIM11182011-CPM.SNDS.pdfAccessed February 28, 2015
   Google Scholar
• PRODUCT MONOGRAPH, CIMZIA® [certolizumab pegol];2015 Available from: http://www.ucb-canada.ca/_up/ucbpharma_ca_en/documents/cimzia_pm_en_15jan2014.pdfAccessed February 28, 2015
   Google Scholar